Lestaurtinib (BioDeep_00000794527)
代谢物信息卡片
Lestaurtinib
化学式: C26H21N3O4 (439.1532)
中文名称: 来他替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC12C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O
InChI: InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:91471
- KEGGdrug: D04696
- PubChem: 126565
- DrugBank: DB06469
- ChEMBL: CHEMBL603469
- CAS: 111358-88-4
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Patrick A Brown, John A Kairalla, Joanne M Hilden, ZoAnn E Dreyer, Andrew J Carroll, Nyla A Heerema, Cindy Wang, Meenakshi Devidas, Lia Gore, Wanda L Salzer, Naomi J Winick, William L Carroll, Elizabeth A Raetz, Michael J Borowitz, Donald Small, Mignon L Loh, Stephen P Hunger. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Leukemia.
2021 05; 35(5):1279-1290. doi:
10.1038/s41375-021-01177-6. [PMID: 33623141] - Varadha Balaji Venkadakrishnan, Adam D DePriest, Sangeeta Kumari, Dhirodatta Senapati, Salma Ben-Salem, Yixue Su, Giridhar Mudduluru, Qiang Hu, Eduardo Cortes, Elena Pop, James L Mohler, Gissou Azabdaftari, Kristopher Attwood, Rajal B Shah, Christina Jamieson, Scott M Dehm, Cristina Magi-Galluzzi, Eric Klein, Nima Sharifi, Song Liu, Hannelore V Heemers. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.
Oncogene.
2019 06; 38(23):4496-4511. doi:
10.1038/s41388-019-0732-7. [PMID: 30742064] - Steven Knapper, Nigel Russell, Amanda Gilkes, Robert K Hills, Rosemary E Gale, James D Cavenagh, Gail Jones, Lars Kjeldsen, Michael R Grunwald, Ian Thomas, Heiko Konig, Mark J Levis, Alan K Burnett. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Blood.
2017 03; 129(9):1143-1154. doi:
10.1182/blood-2016-07-730648. [PMID: 27872058] - Léo Aubert, Matthieu Guilbert, Cyril Corbet, Elisabeth Génot, Eric Adriaenssens, Thierry Chassat, François Bertucci, Thomas Daubon, Nicolas Magné, Xuefen Le Bourhis, Robert-Alain Toillon. NGF-induced TrkA/CD44 association is involved in tumor aggressiveness and resistance to lestaurtinib.
Oncotarget.
2015; 6(12):9807-19. doi:
10.18632/oncotarget.3227. [PMID: 25840418] - Elizabeth O Hexner, John Mascarenhas, Josef Prchal, Gail J Roboz, Maria R Baer, Ellen K Ritchie, David Leibowitz, Erin P Demakos, Crystal Miller, James Siuty, Jill Kleczko, Leah Price, Grace Jeschke, Rona Weinberg, Titiksha Basu, Heike L Pahl, Attilio Orazi, Vesna Najfeld, Roberto Marchioli, Judith D Goldberg, Lewis R Silverman, Ronald Hoffman. Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
Leukemia & lymphoma.
2015; 56(9):2543-51. doi:
10.3109/10428194.2014.1001986. [PMID: 25563429] - Shanshan Tong, Chaonan Sun, Xia Cao, Qianfeng Zheng, Huiyun Zhang, Caleb Kesse Firempong, Yingshu Feng, Yan Yang, Jiangnan Yu, Ximing Xu. Development and thermodynamic evaluation of novel lipid raft stationary phase chromatography for screening potential antitumor agents.
Biomedical chromatography : BMC.
2014 Dec; 28(12):1615-23. doi:
10.1002/bmc.3189. [PMID: 24706535] - Anna Kalota, Grace R Jeschke, Martin Carroll, Elizabeth O Hexner. Intrinsic resistance to JAK2 inhibition in myelofibrosis.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013 Apr; 19(7):1729-39. doi:
10.1158/1078-0432.ccr-12-1907. [PMID: 23386690] - Jane E Minturn, Audrey E Evans, Judith G Villablanca, Gregory A Yanik, Julie R Park, Suzanne Shusterman, Susan Groshen, Edward T Hellriegel, Debra Bensen-Kennedy, Katherine K Matthay, Garrett M Brodeur, John M Maris. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.
Cancer chemotherapy and pharmacology.
2011 Oct; 68(4):1057-65. doi:
10.1007/s00280-011-1581-4. [PMID: 21340605] - Takashi Sato, Xiaochuan Yang, Steven Knapper, Paul White, B Douglas Smith, Steven Galkin, Donald Small, Alan Burnett, Mark Levis. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Blood.
2011 Mar; 117(12):3286-93. doi:
10.1182/blood-2010-01-266742. [PMID: 21263155] - Mark Levis, Farhad Ravandi, Eunice S Wang, Maria R Baer, Alexander Perl, Steven Coutre, Harry Erba, Robert K Stuart, Michele Baccarani, Larry D Cripe, Martin S Tallman, Giovanna Meloni, Lucy A Godley, Amelia A Langston, Sergio Amadori, Ian D Lewis, Arnon Nagler, Richard Stone, Karen Yee, Anjali Advani, Dan Douer, W Wiktor-Jedrzejczak, Gunnar Juliusson, Mark R Litzow, Stephen Petersdorf, Miguel Sanz, Hagop M Kantarjian, Takashi Sato, Lothar Tremmel, Debra M Bensen-Kennedy, Donald Small, B Douglas Smith. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
Blood.
2011 Mar; 117(12):3294-301. doi:
10.1182/blood-2010-08-301796. [PMID: 21270442] - Connie Collins, Michael A Carducci, Mario A Eisenberger, John T Isaacs, Alan W Partin, Roberto Pili, Victoria J Sinibaldi, Janet S Walczak, Samuel R Denmeade. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Cancer biology & therapy.
2007 Sep; 6(9):1360-7. doi:
10.4161/cbt.6.9.4541. [PMID: 17786033] - Mark Levis, Patrick Brown, B Douglas Smith, Adam Stine, Rosalyn Pham, Richard Stone, Daniel Deangelo, Ilene Galinsky, Frank Giles, Elihu Estey, Hagop Kantarjian, Pamela Cohen, Yanfeng Wang, Johannes Roesel, Judith E Karp, Donald Small. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Blood.
2006 Nov; 108(10):3477-83. doi:
10.1182/blood-2006-04-015743. [PMID: 16857987] - John L Marshall, Hedy Kindler, John Deeken, Pankaj Bhargava, Nicholas J Vogelzang, Naiyer Rizvi, Taina Luhtala, Stacy Boylan, Margaret Dordal, Philmore Robertson, Michael J Hawkins, Mark J Ratain. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.
Investigational new drugs.
2005 Jan; 23(1):31-7. doi:
10.1023/b:drug.0000047103.64335.b0. [PMID: 15528978] - Christopher J Strock, Jong-In Park, Mark Rosen, Craig Dionne, Bruce Ruggeri, Susan Jones-Bolin, Samuel R Denmeade, Douglas W Ball, Barry D Nelkin. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
Cancer research.
2003 Sep; 63(17):5559-63. doi:
NULL. [PMID: 14500395]
